{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:45:37Z","timestamp":1769024737450,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.euroneuro.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T22:49:21Z","timestamp":1742078961000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5485-363X","authenticated-orcid":false,"given":"R\u00e9ka","family":"Csehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1roly","family":"Acsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gota","family":"Barab\u00e1ssy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.02.010_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.schres.2024.05.020","article-title":"The effect of second-generation antipsychotics on anxiety\/depression in patients with schizophrenia: a systematic review and meta-analysis","volume":"270","author":"Abdolizadeh","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0002","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bcpt.13384","article-title":"Polypharmacy in schizophrenia","volume":"126","author":"Baandrup","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0003","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/NDT.S301225","article-title":"Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II\/III studies","volume":"17","author":"Barab\u00e1ssy","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0004","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial","volume":"57","author":"Chakos","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.15m10192","article-title":"The effect of Cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials","volume":"77","author":"Citrome","year":"2016","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0006","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","article-title":"Antipsychotic polypharmacy","volume":"35","author":"Correll","year":"2012","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0008","first-page":"675","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence","volume":"74","author":"Correll","year":"2017","journal-title":"JAMa Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0009","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/wps.20516","article-title":"What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?","volume":"17","author":"Correll","year":"2018","journal-title":"World Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2014.00119","article-title":"Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives","volume":"8","author":"Deidda","year":"2014","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/j.eurpsy.2021.2241","article-title":"Disentangling the symptoms of schizophrenia: network analysis in acute phase patients and in patients with predominant negative symptoms","volume":"65","author":"Demyttenaere","year":"2022","journal-title":"Eur. Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0013","first-page":"448","article-title":"Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates","volume":"45","author":"Diniz","year":"2023","journal-title":"Brazil. J. Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0014","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.euroneuro.2013.03.001","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0015","article-title":"Benzodiazepines for schizophrenia","author":"Dold","year":"2012","journal-title":"Cochr. Datab. Syst. Rev."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0016","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","author":"Durgam","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0018","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/YIC.0000000000000187","article-title":"Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II \/III randomized, double-blind, placebo-controlled studies","volume":"32","author":"Earley","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: uses, dangers, and clinical considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0021","doi-asserted-by":"crossref","unstructured":"EMA, 2017. Reagila Summary of product characteristics. https:\/\/doi.org\/10.1163\/187103210x528192.","DOI":"10.1163\/187103210X528192"},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0022","first-page":"1","article-title":"The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials","author":"Falkai","year":"2021","journal-title":"CNS Spectr. Dec"},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0023","unstructured":"FDA, 2022. Cariprazine FDA label [WWW Document]. URL https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204370s009lbl.pdf."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis","volume":"16","author":"Galling","year":"2017","journal-title":"World Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0025","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0026","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0027","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-024-01790-3","article-title":"Comparing the latent state \u2013 trait structure of the PANSS in cariprazine \u2011 medicated and placebo \u2011 controlled patients with acute schizophrenia","author":"Kr\u00fcckl","year":"2024","journal-title":"Eur. Arch. Psych. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0029","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2215-0366(23)00109-8","article-title":"An international research agenda for clozapine-resistant schizophrenia","volume":"10","author":"Luykx","year":"2023","journal-title":"Lancet Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.euroneuro.2018.10.008","article-title":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II\/III studies","volume":"29","author":"Marder","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0031","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2016.01.009","article-title":"Antipsychotic-like effects of zolpidem in Wistar rats","volume":"773","author":"Mierzejewski","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0032","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/brainsci13020173","article-title":"Benzodiazepines and mood stabilizers in schizophrenia patients treated with oral versus long-acting injectable antipsychotics\u2014an observational study","volume":"13","author":"Miron","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0033","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0278-5846(01)00302-5","article-title":"The effects of benzodiazepines on event-related potential indices of automatic and controlled processing in schizophrenia: a preliminary report","volume":"26","author":"Murakami","year":"2002","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euroneuro.2024.12.005","article-title":"Predicting the past: the risks and rewards of post-hoc findings","volume":"92","author":"Oliva","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/wps.20972","article-title":"Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants","volume":"21","author":"Ostuzzi","year":"2022","journal-title":"World Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0036","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jad.2015.07.040","article-title":"Correlates of benzodiazepine use in major depressive disorder: the effect of anhedonia","volume":"187","author":"Rizvi","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0037","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2018.09.006","article-title":"A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone","volume":"204","author":"Robinson","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0038","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.schres.2021.08.005","article-title":"Predictors of response to pharmacological treatments in treatment-resistant schizophrenia \u2013 A systematic review and meta-analysis","volume":"236","author":"Sepp\u00e4l\u00e4","year":"2021","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0039","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/0269881114541013","article-title":"Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review","volume":"29","author":"Sim","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0040","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0041","doi-asserted-by":"crossref","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first-and second-generation antipsychotics: a state-of-the-art clinical review","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk. Manage"},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0042","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/JCP.0000000000001497","article-title":"Use of benzodiazepines and antipsychotic drugs are inversely associated with acute readmission risk in schizophrenia","volume":"42","author":"Str\u00f8mme","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0043","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0044","first-page":"210","article-title":"Representation and outcomes of individuals with Schizophrenia seen in everyday practice who are ineligible for randomized clinical trials","volume":"79","author":"Taipale","year":"2022","journal-title":"JAMA Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0046","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch. Gen. Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0047","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/wps.20309","article-title":"Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis","volume":"15","author":"Vancampfort","year":"2016","journal-title":"World Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0048","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psych."},{"key":"10.1016\/j.euroneuro.2025.02.010_bib0049","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/schbul\/sbaa060","article-title":"Clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group","volume":"46","author":"Wagner","year":"2020","journal-title":"Schizophr. Bull."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X25000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T15:53:52Z","timestamp":1746806032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X25000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"alternative-id":["S0924977X25000422"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.02.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}